Clinical control study on 350 cases of advanced non-small cell lung cancer(NSCLC) treated with Xie's Feiai No.1 formula / 国际中医中药杂志

ABSTRACT

Objective To observe the clinical effects of Xie's Feiai No.1 formula on patients with advanced non-small cell lung cancer (NSCLC) and its influence on body immune system, VEGF (blood vessel endothelia growth factor) and CYFRA21-1 (keratoprotein 21-1). Methods 650 cases of advanced NSCLC were randomized into a treatment group and chemotherapy group, with 350 cases and 300 cases in each group respectively. The treatment group was administrated with Xie's Feiai No.1 formula, while the chemotherapy group was treated with chemotherapy ofGP plan/TP plan. Both groups were treated for 2 months. Results The short-term effective rate was 56.57% in the treatment group, which was superior to 44.33% (P<0.01) in the chemotherapy group; Steady rate KPS score improvement was 85.14% in the treatment group, which was also higher than 27.00% (P<0.01) in the chemotherapy group; besides the levels of total T cell, adjuvant T cell and NK cell in the treatment group were higher than the chemotherapy group, while the levels of Ts cell, VEGF and CYFRA21-1 int the treatment group were lower than the chemotherapy group. Long-term efficacy observation showed that the survival rate of 117 cases with advanced NSCLC was 83.59% in one year and 46.27% in three years in the treatment group, both significantly higher than those in the chemotherapy group (P<0.01).Conclusion Xie's Feiai No.l formula can increase NSCLC patients' survival time, improve quality of life, strengthen immunological function and restrain tumor cells' activities.